S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of  (Ad)pixel
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
Market Wizard who made $95 million for his clients in 2008 (Ad)
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The ONLY Way to Play Markets Like These (Ad)pixel
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of  (Ad)pixel
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
Market Wizard who made $95 million for his clients in 2008 (Ad)
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The ONLY Way to Play Markets Like These (Ad)pixel
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of  (Ad)pixel
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
Market Wizard who made $95 million for his clients in 2008 (Ad)
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The ONLY Way to Play Markets Like These (Ad)pixel
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of  (Ad)pixel
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
Market Wizard who made $95 million for his clients in 2008 (Ad)
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The ONLY Way to Play Markets Like These (Ad)pixel
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
NYSE:NVO

Novo Nordisk A/S - NVO Stock Forecast, Price & News

$104.55
+1.79 (+1.74%)
(As of 08/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$103.71
$105.25
50-Day Range
$99.91
$116.93
52-Week Range
$91.51
$122.16
Volume
1.65 million shs
Average Volume
1.53 million shs
Market Capitalization
$236.59 billion
P/E Ratio
31.21
Dividend Yield
0.79%
Price Target
$682.43

Novo Nordisk A/S MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
552.7% Upside
$682.43 Price Target
Short Interest
Healthy
0.08% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.62mentions of Novo Nordisk A/S in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
22.29%
From $3.41 to $4.17 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.91 out of 5 stars

Medical Sector

45th out of 1,116 stocks

Pharmaceutical Preparations Industry

12th out of 545 stocks

NVO stock logo

About Novo Nordisk A/S (NYSE:NVO) Stock

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Analyst Ratings Changes

A number of equities analysts recently issued reports on NVO shares. UBS Group lowered Novo Nordisk A/S from a "neutral" rating to a "sell" rating in a research note on Tuesday, June 28th. Morgan Stanley raised Novo Nordisk A/S from an "equal weight" rating to an "overweight" rating in a report on Friday, July 15th. Exane BNP Paribas upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a 750.00 price target on the stock in a report on Monday, June 27th. Bryan, Garnier & Co upgraded shares of Novo Nordisk A/S from a "sell" rating to a "neutral" rating in a research note on Thursday, May 5th. Finally, JPMorgan Chase & Co. upgraded shares of Novo Nordisk A/S from a "neutral" rating to an "overweight" rating in a research note on Tuesday, June 7th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Moderate Buy" and an average price target of $682.43.

Novo Nordisk A/S Price Performance

NVO Stock traded up $1.79 during mid-day trading on Friday, reaching $104.55. 1,651,425 shares of the company's stock were exchanged, compared to its average volume of 1,528,623. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.94 and a quick ratio of 0.74. Novo Nordisk A/S has a 12-month low of $91.51 and a 12-month high of $122.16. The stock's 50 day moving average is $109.71 and its 200 day moving average is $108.79. The company has a market cap of $236.59 billion, a price-to-earnings ratio of 30.67, a price-to-earnings-growth ratio of 1.86 and a beta of 0.44.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, August 23rd. Stockholders of record on Monday, August 15th will be given a dividend of $0.5836 per share. The ex-dividend date is Friday, August 12th. This represents a dividend yield of 1.1%. Novo Nordisk A/S's dividend payout ratio (DPR) is 24.18%.

Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

NVO Stock News Headlines

Analysts Set Novo Nordisk A/S (NYSE:NVO) PT at $697.50
How Eli Lilly Is Thinning Out the Competition
The One Ticker Retirement Plan Over the Shoulder Demo Now Available
Market Wizard Larry Benedict crushed the market in 2022. But he hasn’t done it with a “traditional” method… For a limited time, he’s sharing a free over-the-shoulder “demo” of his strategy in action.
Novo Nordisk: Looming Danger In An Excellent Business
Novo Nordisk (NVO) Q2 2022 Earnings Call Transcript
Reclusive trader scores 20 straight years of winning trades. Learn how
He had 20 straight years of winning trades without a single losing year… That put his hedge fund in the top 1% of Barron’s rankings. He was featured in the popular trading book, "Hedge Fund Market Wizards, How Winning Traders Win…”
Oversold Conditions For Novo-Nordisk (NVO)
Brokerages Set Novo Nordisk A/S (NYSE:NVO) PT at $697.50
See More Headlines
Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

NVO Company Calendar

Last Earnings
11/02/2021
Ex-Dividend for 8/23 Dividend
8/12/2022
Today
8/19/2022
Dividend Payable
8/23/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
45,000
Year Founded
1923

Price Target and Rating

Average Stock Price Forecast
$682.43
High Stock Price Forecast
$900.00
Low Stock Price Forecast
$130.00
Forecasted Upside/Downside
+552.7%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
19 Analysts

Profitability

Net Income
$7.60 billion
Pretax Margin
39.94%

Debt

Sales & Book Value

Annual Sales
$22.40 billion
Cash Flow
$3.62 per share
Book Value
$4.70 per share

Miscellaneous

Outstanding Shares
2,262,969,000
Free Float
2,261,385,000
Market Cap
$236.59 billion
Optionable
Optionable
Beta
0.44

Social Links


Key Executives

  • Mr. Lars Fruergaard JorgensenMr. Lars Fruergaard Jorgensen (Age 56)
    Pres, CEO & Member of Management Board
    Comp: $4.81M
  • Mr. Karsten Munk KnudsenMr. Karsten Munk Knudsen (Age 51)
    Exec. VP, CFO & Member of the Management Board
    Comp: $1.78M
  • Mr. Henrik Ehlers Wulff (Age 52)
    Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board
    Comp: $1.87M
  • Ms. Camilla Sylvest (Age 50)
    Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board
    Comp: $1.78M
  • Ms. Monique Carter (Age 49)
    Exec. VP, Head of People & Organisation and Member of Management Board
    Comp: $1.35M
  • Mr. Maziar Mike Doustdar (Age 52)
    Exec. VP, Head of International Operations & Member of the Management Board
  • Mr. Douglas J. Langa (Age 56)
    Exec. VP, Head of North America Operations & Member of Management Board
  • Mr. Ludovic Helfgott (Age 48)
    Exec. VP, Head of Rare Disease & Member of Management Board
  • Dr. Martin Holst Lange (Age 52)
    Exec. VP, Head of Devel. & Member of the Management Board
  • Dr. Marcus  Schindler Ph.D.Dr. Marcus Schindler Ph.D. (Age 56)
    EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board













NVO Stock - Frequently Asked Questions

Should I buy or sell Novo Nordisk A/S stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View NVO analyst ratings
or view top-rated stocks.

What is Novo Nordisk A/S's stock price forecast for 2022?

19 equities research analysts have issued 1 year target prices for Novo Nordisk A/S's shares. Their NVO share price forecasts range from $130.00 to $900.00. On average, they anticipate the company's stock price to reach $682.43 in the next twelve months. This suggests a possible upside of 552.7% from the stock's current price.
View analysts price targets for NVO
or view top-rated stocks among Wall Street analysts.

How have NVO shares performed in 2022?

Novo Nordisk A/S's stock was trading at $112.00 at the beginning of the year. Since then, NVO stock has decreased by 6.7% and is now trading at $104.55.
View the best growth stocks for 2022 here
.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 1,310,000 shares, an increase of 26.0% from the July 15th total of 1,040,000 shares. Based on an average daily volume of 1,480,000 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.1% of the shares of the company are sold short.
View Novo Nordisk A/S's Short Interest
.

When is Novo Nordisk A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our NVO earnings forecast
.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings results on Tuesday, November, 2nd. The company reported $5.27 EPS for the quarter, beating analysts' consensus estimates of $0.78 by $4.49. The firm had revenue of $5.65 billion for the quarter, compared to analyst estimates of $5.64 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 72.10% and a net margin of 32.14%.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a semi-annual dividend on Friday, August 5th. Investors of record on Monday, August 15th will be paid a dividend of $0.5836 per share on Tuesday, August 23rd. This represents a dividend yield of 1.1%. The ex-dividend date is Friday, August 12th.
Read our dividend analysis for NVO
.

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S (NYSE:NVO) pays an annual dividend of $0.81 per share and currently has a dividend yield of 0.79%. The dividend payout ratio is 24.18%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVO will have a dividend payout ratio of 19.42% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVO.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S issued an update on its FY 2022 earnings guidance on Friday, August, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $22.59 billion-$23.40 billion, compared to the consensus revenue estimate of $23.52 billion.

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among the company's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.77%), Jennison Associates LLC (0.46%), Loomis Sayles & Co. L P (0.23%), Folketrygdfondet (0.18%), WCM Investment Management LLC (0.17%) and State Street Corp (0.16%).
View institutional ownership trends
.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $104.55.

How much money does Novo Nordisk A/S make?

Novo Nordisk A/S (NYSE:NVO) has a market capitalization of $236.59 billion and generates $22.40 billion in revenue each year. The company earns $7.60 billion in net income (profit) each year or $3.35 on an earnings per share basis.

How many employees does Novo Nordisk A/S have?

The company employs 45,000 workers across the globe.

Does Novo Nordisk A/S have any subsidiaries?
The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., CS Solar Fund XIV LLC, Calibrium, Corvidia, Corvidia Therapeutics Inc., Dicerna Pharmaceuticals, Dicerna Pharmaceuticals Inc., Emisphere Technologies, Emisphere Technologies Inc., MB2 LLC, NNE A/S, Neotope Neuroscience Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk (Shanghai) Pharma Trading Co. Ltd., Novo Nordisk B.V., Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comércio Produtos Farmacêuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Finance (Netherlands) B.V., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungária Kft., Novo Nordisk Inc., Novo Nordisk India Holding Pte Ltd., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk North America Operations A/S, Novo Nordisk Norway AS, Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZE, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma Sp.z.o.o., Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals A/S, Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Pharmatech US Inc., Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region China A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Saudi for Trading, Novo Nordisk Scandinavia AB, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Commercial Holdings Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representación C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, Ziylo, and Ziylo Limited.
Read More
When was Novo Nordisk A/S founded?

Novo Nordisk A/S was founded in 1923.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The official website for the company is www.novonordisk.com. The company can be reached via phone at (454) 444-8888, via email at phak@novonordisk.com, or via fax at 45-4449-0555.

This page (NYSE:NVO) was last updated on 8/20/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.